drugset
drugset / Trial / NCT06905314

A Single Ascending Dose of HRS-4029 in Healthy Subjects

NCT06905314 ↗

Phase 1 Not yet recruiting 55 enrolled Beijing Suncadia Pharmaceuticals Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-4029 following a single intravenous dose administration in healthy subjects.

Timeline

Start
2025-04
Primary completion
2025-10
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-4029 Unknown — Intravenous

Indications

ischemic stroke